Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CertaraCERT +0.86%65 EBITDA Margin % is 12.71% as of Jun. 2026, which is 37% below its 10-year median of 20.09. GuruFocus rates CERT with a GF Score™ of 65/100 and a GF Value™ of $12.84 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 664 Healthcare Providers & Services companies, Certara ranks better than 72.59% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Certara's EBITDA for the
three
months ended in Jun. 2026 was $11.9 Mil. Certara's Revenue for the
three
months ended in Jun. 2026 was $93.3 Mil. Therefore, Certara's EBITDA margin for the quarter that ended in Jun. 2026 was 12.71%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Certara EBITDA Margin % Related Terms
Certara EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Certara's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CERT vs SDGR, OMDA, GDRX: EBITDA Margin % Comparison
For the Health Information Services subindustry, Certara's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Certara EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Certara's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Certara's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Certara (CERT) has a EBITDA Margin % of 12.71% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Certara and its competitors. This is 37% below median its historical median of 20.09. Over the past decade, Certara's EBITDA Margin % has ranged from 6.73 to 28.97. According to the industry distribution chart, Certara ranks #182 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 27.4%.
Is Certara's EBITDA Margin % too high?
Certara's current EBITDA Margin % of 12.71% is 37% below median its 10-year median of 20.09. Over the past 10 years, this metric has ranged from a low of 6.73 to a high of 28.97. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Certara's value of 12.71% is 24.5% above this industry median. Based on the distribution chart, Certara ranks #182 out of 664 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Certara has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Certara's EBITDA Margin % compare to SDGR and OMDA?
According to the Healthcare Providers & Services industry distribution chart, Certara ranks #182 out of 664 companies for EBITDA Margin %. This puts Certara in the upper half of its industry. The industry median EBITDA Margin % is 10.21. Certara's value of 12.71% is 24.5% above this benchmark. Historically, Certara's own EBITDA Margin % has ranged from 6.73 to 28.97 over the past decade. While the company's 10-year median is 20.09 vs. the industry median of 10.21, Certara has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Certara's current EBITDA Margin % of 12.71% is 24.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Certara and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Certara's current EBITDA Margin % is 12.71%, which is 37% below median its own 10-year median of 20.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Certara stock overvalued right now?
Based on GuruFocus' analysis, Certara (CERT) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.84, compared to a current price of $8.20 — trading 36.1% below its estimated fair value. The current EBITDA Margin % is 12.71%, which is 37% below median its 10-year median of 20.09 and 24.5% above the Healthcare Providers & Services industry median of 10.21. Certara's overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Certara (CERT), the current EBITDA Margin % is 12.71% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Certara (CERT) Overvalued in 2026?
Based on GuruFocus' analysis, Certara stock appears to be undervalued.
The current stock price of $8.20 is trading 36.1% below its estimated GF Value™ of $12.84.
GuruFocus considers Certara to be Significantly Undervalued.
Key valuation signals for CERT:
EBITDA Margin %: 12.71% (37% below median its 10-year median of 20.09)
GF Value™: $12.84 vs. price of $8.20 (36.1% below fair value)
Industry Position: 24.5% above the Healthcare Providers & Services median (#182 of 664)
No single metric tells the full story. See the CERT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
65GF Score
Get the complete analysis for CERT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERT has been successfully added to your 
